On September 29, 2020, LifeSci Acquisition Corp. (LSAC), a blank check company targeting the biopharma, medical technology, digital health, and healthcare services sectors and Vincera Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that they have entered into a definitive agreement for a business combination.

The combined company is expected to have approximately $60 million in cash at closing. In addition, it is expected that LSAC will be renamed Vincera Pharma, Inc. and the combined company’s common stock will remain listed on Nasdaq under the ticker symbol “VINC.” Wilson Sonsini represented LifeSci Acquisition Corp. on IP matters related to the transaction.

Post-closing, stockholders will include Acuta Capital, RTW Investments, Surveyor Capital (a Citadel company), Logos Capital, EcoR1 Capital, Perceptive Advisors, Boxer Capital of Tavistock Group, Monashee Investment Management, Altium Capital, and Affinity Asset Advisors. Proceeds from the transaction will provide Vincera with capital and the flexibility of being a publicly listed company to accelerate the growth of their pipeline, currently driven by an exclusive option to license agreement with Bayer for an oncology portfolio, which includes a highly selective, clinical-stage PTEFb/CDK9 inhibitor, as well as a preclinical bioconjugation platform developed to overcome the limitations of antibody and small molecule drug conjugates.

The Wilson Sonsini team that advised LSAC on IP matters related to the transaction includes Michael Hostetler, Deborah Smith, Céline Bonnefous, Erin Boyle Anderson, Grant Margulieux, David Clark, and Dylan Kahl.

For more information, please see LSAC's press release.